Fenliping® Ibuprofen Injection was approved, indicated in pediatric patients 6 months and older for the management of pain and reduction of fever.
Ranked 71st in the TOP100 of Pharmaceutical Enterprises in China.
Class 1 new drug Ugretin tablets proceed into Phase II clinical trials.
Anduoxi® Etoricoxib tablets was approved, ready to be launched in the market.
Chengdu Unovel Pharmaceutical Co., Ltd. was established.
Won the title of "National Intellectual Property Advantage Enterprise".
Ibuprofen Injection was approved for drug registration and listed in the Catalogue of Listed Drugs in China as a reference listed drug.
Became the first passing the consistency evaluation on Bisoprolol Fumarate Tablets in China, which has been listed the Catalogue of Listed Drugs in China.
Chairwoman of Easton Biopharma Ms. Wang Ying was awarded as the leading talent of national "Ten Thousand People Plan".
Easton Biopharma was certified the first CEP (R0-CEP 2016-139-Rev 00) for Bisoprolol Fumarate.
Qingmu recognized as "National High-tech Enterprise"; Winning the honorary title "Outstanding Enterprise of Chengdu Intellectual Property".
Easton Biopharma won the title of "Intellectual Property Awards of Chengdu".
Easton Biopharma passed three-level enterprise inspection of production safety standardization.
Shanmeng® Caffeine Citrate injection recieved registration approval and lauched in the market
Shuode Pharmaceutical was founded.
Small-volume injection workshop 201 has been certificed with GMP again.
Xizang Runhe Pharmaceutical was founded.
Shareholding reform was completed, Chengdu Easton Biopharmaceuticals Co.,Ltd was established.
ClassⅠnew drugs obtained clinical approval, progressing into the phase I clinical research.
lyophillization facility is certified with new GMP.
APIs site Sichuan Qingmu is certified with new GMP.
R&D Center of Easton Pharma is recognized as Sichuan Enterprise Technology Center.
Production line of tablet and capsule passed new GMP.
The construction of Qingmu API site was completed, launched a global strategy for the development of API.
The company's "postdoctoral workstation" was approved to carry out post-doctoral training and implement dual-channel training project.
Easton Pharma recognized as "Industry Technical Center of Chengdu".
Aimokun® Sodium Ibandronate Injection obtained registration approval.
Recieved GMP certificates of Ibandronate Sodium, Olanzapine and Naloxone HCl API.
Qingmu API site was established.
Ruisixin® Fasudil Hydrochloride Injection has obatined registration approvals.
Easton Pharma (for its Small-volume injection) became the first company of Southwestern China which passed the new GMP.
Four registration approvals were obtained.
Tablets, Capsule production line of Easton Pharma approved by CFDA. Three registration approvals for API were obtained.
Easton Pharma was established as the formulation site.
Mingyang Pharma was established as the API site.
Sunheal established and received GSP certificate. R&D center established.